$2200 | SAVE $300 | Single User
$4400 | SAVE $600 | Site License
$6600 | SAVE $900 | Enterprise License

Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
[Published by Global Data]

Published by Global Data: 29 Jul 2016 | 27258 | In Stock
Related Topics: Clinical Trials

Introduction

Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016" provides an overview of Metastatic Hepatocellular Carcinoma (HCC) clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

  • Table of Contents

    Table of Contents 2

    List of Tables 3

    List of Figures 4

    Report Guidance 5

    Clinical Trials by Region 6

    Clinical Trials and Average Enrollment by Country 7

    Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

    Top Five Countries Contributing to Clinical Trials in Europe 11

    Top Countries Contributing to Clinical Trials in North America 12

    Top Countries Contributing to Clinical Trials in Middle East and Africa 13

    Top Countries Contributing to Clinical Trials in Central and South America 14

    Clinical Trials by G7 Countries: Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials 15

    Clinical Trials by Phase in G7 Countries 16

    Clinical Trials in G7 Countries by Trial Status 17

    Clinical Trials by E7 Countries: Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials 18

    Clinical Trials by Phase in E7 Countries 19

    Clinical Trials in E7 Countries by Trial Status 20

    Clinical Trials by Phase 21

    In Progress Trials by Phase 22

    Clinical Trials by Trial Status 23

    Clinical Trials by End Point Status 24

    Subjects Recruited Over a Period of Time 25

    Clinical Trials by Sponsor Type 26

    Prominent Sponsors 27

    Top Companies Participating in Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials 29

    Prominent Drugs 31

    Clinical Trial Profile Snapshots 32

    Appendix 120

    Abbreviations 120

    Definitions 120

    Research Methodology 121

    Secondary Research 121

    About GlobalData 122

    Contact Us 122

    Disclaimer 122

    Source 123

List Of Tables
in Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Tables

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Region, 2016* 6

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14

Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Phase, 2016* 21

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31

List Of Figures, Charts and Diagrams
in Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Figures

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14

Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31

GlobalData Methodology 121

Additional Details

Publisher

Global Data

Publisher Information

Reference

27258 | GDHC3635CTIDB

Number of Pages

123

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $612 (normally
USD $695)
More Info

This report is published by Global Data

Download Free Report Summary PDF

Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...